Your browser doesn't support javascript.
loading
Safety and efficacy of the FAKHRAVAC compared with BBIBP-Corv2 against SARS-CoV-2 in adults: a non-inferiority multi-center trial.
Solaymani-Dodaran, Masoud; Basiri, Pouria; Moradi, Milad; Gohari, Kimiya; Sheidaei, Ali; Ahi, Mohammadreza; Ghafoori Naeeni, Farzad; Ansarifar, Akram; Rahimi, Zahra; Gholami, Fatemeh; Karimi Rahjerdi, Ahmad; Hamidi Farahani, Ramin; Naderi Saffar, Kosar; Ghasemi, Soheil; Shooshtari, Ali; Honari, Mohsen; Mozafari, Ali; Khodaverdloo, Samane; Forooghizadeh, Mohsen.
Afiliación
  • Solaymani-Dodaran M; Clinical Trial Center (CTC) of Iran University of Medical Sciences, Tehran, Iran.
  • Basiri P; Clinical Trial Center (CTC) of Iran University of Medical Sciences, Tehran, Iran.
  • Moradi M; Stem Cell Technology Research Center (STRC), Tehran, Iran.
  • Gohari K; Clinical Trial Center (CTC) of Iran University of Medical Sciences, Tehran, Iran.
  • Sheidaei A; Clinical Trial Center (CTC) of Iran University of Medical Sciences, Tehran, Iran.
  • Ahi M; Clinical Trial Center (CTC) of Iran University of Medical Sciences, Tehran, Iran.
  • Ghafoori Naeeni F; Stem Cell Technology Research Center (STRC), Tehran, Iran.
  • Ansarifar A; Clinical Trial Center (CTC) of Iran University of Medical Sciences, Tehran, Iran.
  • Rahimi Z; Clinical Trial Center (CTC) of Iran University of Medical Sciences, Tehran, Iran.
  • Gholami F; Clinical Trial Center (CTC) of Iran University of Medical Sciences, Tehran, Iran.
  • Karimi Rahjerdi A; Milad Daro Noor Pharmaceutical (MDNP) Company, Tehran, Iran.
  • Hamidi Farahani R; AJA University of Medical Sciences, Tehran, Iran.
  • Naderi Saffar K; Stem Cell Technology Research Center (STRC), Tehran, Iran.
  • Ghasemi S; Milad Daro Noor Pharmaceutical (MDNP) Company, Tehran, Iran.
  • Shooshtari A; Milad Daro Noor Pharmaceutical (MDNP) Company, Tehran, Iran.
  • Honari M; Milad Daro Noor Pharmaceutical (MDNP) Company, Tehran, Iran.
  • Mozafari A; Milad Daro Noor Pharmaceutical (MDNP) Company, Tehran, Iran.
  • Khodaverdloo S; Milad Daro Noor Pharmaceutical (MDNP) Company, Tehran, Iran.
  • Forooghizadeh M; Malek Ashtar University of Technology, Tehran, Iran. mohsenforooghizadeh@gmail.com.
Virol J ; 20(1): 154, 2023 07 18.
Article en En | MEDLINE | ID: mdl-37464440

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Clinical_trials Límite: Adult / Humans País/Región como asunto: Asia Idioma: En Revista: Virol J Asunto de la revista: VIROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Irán

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Clinical_trials Límite: Adult / Humans País/Región como asunto: Asia Idioma: En Revista: Virol J Asunto de la revista: VIROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Irán